FDA approves two minimally invasive heartburn treatments
This article was originally published in Clinica
The US FDA has approved Curon Medical's radiofrequency-based (RF) Stretta system for use in chronic heartburn, making it the second minimally invasive treatment for the condition to be cleared for marketing in a month. Earlier in April, CR Bard's endoscopic suturing system was approved for use in patients with chronic heartburn, or gastroesophageal reflux disease (GERD) (see Clinica No 904, p 18).
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.